Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

NCT05530421 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT05530421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05530421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Recruiting
Start date
March 26, 2023
Completion date
March 26, 2030
Enrollment
33 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and refractory multiple myeloma